Product Name Anti-PCSK9 antibody
Catalog No PAab06227
Alternative Name NARC1
Purification Immunogen affinity purified
Purity 95% as determined by SDS-PAGE
Storage PBS with 0.02% sodium azide and 50% glycerol pH 7.3 , -20Centigrade for 24 months (Avoid repeated freeze / thaw cycles.)
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non- acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)- mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Immunogen proprotein convertase subtilisin/kexin type 9
Specificity Human,Mouse ,Rat
Tested Application ELISA,WB,IHC
Immunohistochemistry of paraffin-embedded human colon cancer tissue slide using PCSK9 Antibody at dilution of 1:200 heat mediated antigen retrieved with Tris-EDTA bufferpH9).
COLO 320 cells were subjected to SDS PAGE followed by western blot with PAab06227(PCSK9 antibody) at dilution of 1:500
Uniprot ID Q8NBP7